Recombinant human replication-deficient adenovirus comprising a modified nucleic acid encoding the Marburg virus envelope glycoprotein

US11453704B2 · kind B2 · utility

Assignee

• Academy of Military Medical Sciences · CN

Inventors

• Wei-Ming Chen · Hsinchu, TW
• Shipo Wu · Beijing, CN
• Lihua Hou · Beijing, CN
• Yanbo Wen · Beijing, CN
• Zhe Zhang · Simpsonville, US
• Busen Wang · Beijing, CN
• Xiaohong Song · Beijing, CN
• Jinlong Zhang · 红钢城街道, CN
• Ling Fu · Beijing, CN

Key dates

• Filing date: Aug 27, 2018
• Grant date: Sep 27, 2022
• Expiry date: Oct 17, 2038

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2760/14234
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to a nucleotide sequence as shown in SEQ ID NO: 1 for encoding a Marburg virus envelope glycoprotein, and to a human replication-deficient recombinant adenovirus capable of expressing the nucleotide sequence and a preparation method therefor, as well as an application thereof in the preparation of a vaccine against Marburg virus disease. The vaccine uses an E1 and E3 deleted replication-deficient human type-5 adenovirus as a vector, and HEK293 cells integrating an adenovirus E1 gene as a packaging cell line, and a protective antigen gene carried is a codon-optimized Marburg virus Angola strain envelope glycoprotein gene. After codon optimization of the envelope glycoprotein gene, significant expression of envelope glycoprotein can be detected in transfected cells.